Central Nervous System Therapeutics Market Report 2026

Central Nervous System Therapeutics Market Overview

• Central Nervous System Therapeutics market size has reached to $134.99 billion in 2025 • Expected to grow to $206.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Increase In Mental Health Disorders Is Fueling Market Growth Due To Increasing Exposure To Chronic Stress • Market Trend: Advancements In Capsid Engineering For Targeted Central Nervous System (CNS) Gene Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Central Nervous System Therapeutics Market?

Central nervous system therapeutics refers to drugs and treatments designed to manage and treat disorders affecting the brain and spinal cord. These include conditions such as depression, epilepsy, Parkinson’s disease, and multiple sclerosis. It aims to restore neurological function, alleviate symptoms, and improve patients' quality of life. They may include pharmaceuticals, biologics, and advanced neurotechnological interventions. The main drug class of central nervous system therapeutics are anesthetics, anticonvulsants, antiemetics, central nervous system (CNS) stimulants, pain relievers, and others. Anesthetics are medicines that stop pain or make you unconscious during medical procedures. The multiple diseases include neurovascular diseases, mental health, degenerative disorders, genetic diseases, substance abuse disorders, autoimmune and inflammatory diseases, central nervous system (CNS) trauma, infectious diseases, central nervous system (CNS) cancer, and others. The various distribution channels, such as hospital pharmacies, retail pharmacies, and others and cater to various applications, such as hospital, clinic, homecare, and others

What Is The Central Nervous System Therapeutics Market Growth Forecast?

The central nervous system therapeutics market size is expected to see strong growth in the next few years. It will grow to $206.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to development of novel neuroprotective agents, growth in biologics and gene-based therapies, increasing investment in neuroscience research, rising adoption of personalized medicine, expanding access to cns treatments in emerging markets. Major trends in the forecast period include rising prevalence of neurological and mental health disorders, growing adoption of combination therapies for cns diseases, increasing focus on long-term disease management and symptom control, expansion of homecare-based cns treatment solutions, improved drug formulations with better blood-brain barrier penetration.

Global Central Nervous System Therapeutics Market Segmentation

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes 2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels 4) By Application: Hospital, Clinic, Homecare, Other Applications Subsegments: 1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics 2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents 3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids 4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives 5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief 6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

What Is The Driver Of The Central Nervous System Therapeutics Market?

The increasing prevalence of mental health disorders is expected to propel the growth of the central nervous system therapeutics market going forward. Mental health disorders refer to a wide range of conditions that affect a person’s thinking, feeling, behavior, or mood, such as depression, anxiety disorders, schizophrenia, and bipolar disorder. The rising prevalence of mental health disorders is due to increasing exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to conditions such as anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics help treat mental health disorders by targeting brain chemicals and neural pathways involved in mood, behavior, and cognition. For instance, in December 2025, according to the report published by Bristol City Council, a UK-based local government authority, in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022-23, marking a 6.0% rise from 2021-22. Therefore, the increasing prevalence of mental health disorders is driving the growth of the central nervous system therapeutics industry.

Key Players In The Global Central Nervous System Therapeutics Market

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

Global Central Nervous System Therapeutics Market Trends and Insights

Major companies operating in the central nervous system therapeutics market are focusing on developing innovative solutions such as capsid engineering to enhance targeted gene delivery, therapeutic efficacy, and blood-brain barrier penetration for improved treatment of neurological disorders. Capsid engineering refers to the modification and optimization of the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), used in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF 01, a novel adeno associated virus (AAV) for central nervous system (CNS) delivery using their proprietary ALIGATER platform. It demonstrated significantly enhanced transduction efficiency and safety compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Remarkably, equivalent expression levels to AAV9 were attained at just one-fifth of the dose, highlighting its superior potency. Additionally, the vector showed substantially reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These results underscore the vector’s potential to enhance CNS gene therapy outcomes with improved precision and lower systemic risk.

What Are Latest Mergers And Acquisitions In The Central Nervous System Therapeutics Market?

In June 2025, Supernus Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Sage Therapeutics Inc. for an undisclosed amount. Through this acquisition, Supernus Pharmaceuticals Inc. aims to expand its neuroscience portfolio, strengthen its position in the central nervous system (CNS) market, and accelerate the development of innovative treatments for depression and other mood disorders. Sage Therapeutics Inc. is a US-based biopharmaceutical company that focuses on central nervous system therapeutics.

Regional Insights

North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Central Nervous System Therapeutics Market?

The central nervous system therapeutics market consists of sales of sodium channel blockers, amphetamines, and neuroprotective agents. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Central Nervous System Therapeutics Market Report 2026?

The central nervous system therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.